Furthermore, KRAS mutations have been linked to the upregulation of the immune checkpoint molecule PD-L1, suggesting that CRISPR-mediated knockout of PD-1 or PD-L1 could improve the efficacy of immunotherapies in KRAS-mutant lung cancers [115]. This evidence concerns the gene KRAS and lung cancer.